In this study, data from a 12-week, phase Ib study in naïve T2DM patients were used to quantify the effects of PB-119, a long-acting GLP-1 RA, on glycemic control and to compare it with exenatide. Here, GLP1R is linked to type 2 diabetes mellitus.